Related Experiment Videos
Transurethral resection and intravesical therapy of superficial bladder tumors
1Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York.
Abstract:
The treatment of superficial bladder cancer is aimed at eradicating existing disease, inhibiting tumor recurrence, and preventing progression to invasion or metastasis. Transurethral resection is the primary modality, with intravesical therapy used in some cases to kill residual overt or occult carcinoma and premalignant lesions. Among the agents tested extensively, BCG appears to be more effective than mitomycin C, doxorubicin, or thiotepa, especially against carcinoma in situ. A number of questions remain to be answered about the management of this disease.
Insights
The primary treatment for superficial bladder cancer is transurethral resection, with intravesical therapies like BCG showing effectiveness against carcinoma in situ. Further research is needed for optimal management strategies.
Area of Science:
- Urology
- Oncology
Background:
- Superficial bladder cancer requires treatment to eliminate disease, prevent recurrence, and stop progression.
- Transurethral resection is the standard initial treatment.
- Intravesical therapy is employed to target residual cancer cells and precancerous conditions.
Purpose of the Study:
- To review current treatment strategies for superficial bladder cancer.
- To compare the efficacy of different intravesical agents.
- To identify areas requiring further investigation in bladder cancer management.
Main Methods:
- Review of existing literature on superficial bladder cancer treatment.
- Analysis of data comparing transurethral resection and various intravesical therapies.
- Evaluation of outcomes including disease eradication, recurrence rates, and progression.
Main Results:
- Transurethral resection is the cornerstone of superficial bladder cancer treatment.
- Intravesical Bacillus Calmette-Guerin (BCG) demonstrates superior efficacy compared to mitomycin C, doxorubicin, and thiotepa.
- BCG is particularly effective against carcinoma in situ, a high-risk form of bladder cancer.
Conclusions:
- BCG is a highly effective intravesical agent for superficial bladder cancer, especially carcinoma in situ.
- While effective, challenges and unanswered questions remain in the comprehensive management of this condition.
- Further research is essential to refine treatment protocols and improve patient outcomes.